Remove 2025 Remove Dosage Remove Packaging
article thumbnail

Sustainability continues to steer pharmaceutical packaging market

European Pharmaceutical Review

The worldwide pharmaceutical container packaging market is expected to rise in revenue from $104.12 billion in 2025 to approximately $174.45 billion by 2033, according to a study published by Towards Packaging. Specifically, the “high quality of biodegradable and recyclable packaging materials” are driving the market.

article thumbnail

WuXi STA breaks ground on new Delaware manufacturing facility

European Pharmaceutical Review

The second facility for WuXi STA in the US, Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labelling, storage and distribution services for clinical trial materials and commercial drug products.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How much does semaglutide cost per month?

The Checkup by Singlecare

For those licensed by the state, the deadline is April 22, 2025. For those licensed by the FDA, the deadline is May 22, 2025. The list price of brand-name forms of semaglutide ranges from $998$1,349 per package, typically a months supply, depending on the dosage prescribed. How much is semaglutide without insurance?

article thumbnail

Covid-19 Omicron boosters will reinvigorate injectables manufacturing

Pharmaceutical Technology

Injectables and their packaging requirements have never been more important to marketed treatments, given the volume of vaccines being packaged that are required to tackle the Covid-19 pandemic, as well as the rising presence of biologics in pipelines and their marketed approvals. with BARDA (Washington DC).

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™